Rigel Pharmaceuticals (RIGL) Return on Capital Employed (2011 - 2026)
Rigel Pharmaceuticals' quarterly Return on Capital Employed came in at 29.69% in Q1 2026, down 1282.0% year-on-year from 2.51% in Q1 2025, and down 34.02% quarter-over-quarter from 45.0% in Q4 2025.
Rigel Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 29.69% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1282.0% year-over-year to 29.69%; the trailing twelve-month figure through Mar 2026 stood at 29.69% (down 1282.0% YoY), and the FY2025 full-year result was 52.38%, up 2108.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.69%, down from 45.0% in the prior quarter.
- The five-year high for Return on Capital Employed was 99.87% in Q2 2025, with the low at 106.05% in Q3 2022.
- Average Return on Capital Employed over 5 years is 13.54%, with a median of 30.0% recorded in 2023.
- Year-over-year, Return on Capital Employed slumped 9870 bps in 2022 and soared 11298 bps in 2025.
- Tracing RIGL's Return on Capital Employed over 5 years: stood at 93.0% in 2022, then surged by 65 bps to 32.52% in 2023, then surged by 184 bps to 27.37% in 2024, then jumped by 64 bps to 45.0% in 2025, then sank by 34 bps to 29.69% in 2026.
- The last three Return on Capital Employed figures came in at 29.69% (Q1 2026), 45.0% (Q4 2025), and 91.34% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 29.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.69% |
| Dec 31, 2025 | 45.00% |
| Sep 30, 2025 | 91.34% |
| Jun 30, 2025 | 99.87% |
| Mar 31, 2025 | 42.51% |
| Dec 31, 2024 | 27.37% |
| Sep 30, 2024 | 11.94% |
| Jun 30, 2024 | -13.10% |
| Mar 31, 2024 | -30.27% |
| Dec 31, 2023 | -32.52% |
| Sep 30, 2023 | -30.00% |
| Jun 30, 2023 | -44.96% |
| Mar 31, 2023 | -50.36% |
| Dec 31, 2022 | -93.00% |
| Sep 30, 2022 | -106.05% |
| Jun 30, 2022 | -96.23% |
| Mar 31, 2022 | -81.34% |
| Dec 31, 2021 | -11.02% |
| Sep 30, 2021 | -7.35% |
| Jun 30, 2021 | -2.61% |
| Mar 31, 2021 | -7.42% |
| Dec 31, 2020 | -38.18% |
| Sep 30, 2020 | -28.52% |
| Jun 30, 2020 | -24.30% |
| Mar 31, 2020 | -25.97% |
| Dec 31, 2019 | -73.81% |
| Sep 30, 2019 | -39.35% |
| Jun 30, 2019 | -45.23% |
| Mar 31, 2019 | -51.10% |
| Dec 31, 2018 | -70.29% |
| Sep 30, 2018 | -90.16% |
| Jun 30, 2018 | -92.46% |
| Mar 31, 2018 | -97.76% |
| Dec 31, 2017 | -103.61% |
| Sep 30, 2017 | -109.20% |
| Jun 30, 2017 | -95.54% |
| Mar 31, 2017 | -94.33% |
| Dec 31, 2016 | -114.71% |
| Sep 30, 2016 | -90.94% |
| Jun 30, 2016 | -62.03% |
| Mar 31, 2016 | -55.33% |
| Dec 31, 2015 | -50.90% |
| Sep 30, 2015 | -56.34% |
| Jun 30, 2015 | -61.56% |
| Mar 31, 2015 | -69.37% |
| Dec 31, 2014 | -63.08% |
| Sep 30, 2014 | -52.78% |
| Jun 30, 2014 | -48.53% |
| Mar 31, 2014 | -41.65% |
| Dec 31, 2013 | -40.21% |
| Sep 30, 2013 | -40.50% |
| Jun 30, 2013 | -37.82% |
| Mar 31, 2013 | -35.42% |
| Dec 31, 2012 | -41.41% |
| Sep 30, 2012 | -51.44% |
| Jun 30, 2012 | -42.93% |
| Mar 31, 2012 | -37.40% |
| Dec 31, 2011 | -33.88% |
| Sep 30, 2011 | -29.20% |